Published in J Med Chem on September 12, 2012
Selective inhibitors of protein methyltransferases. J Med Chem (2014) 1.01
Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. J Med Chem (2013) 1.00
Small Molecule Inhibitors of Protein Arginine Methyltransferases. Expert Opin Investig Drugs (2016) 0.89
Diamidine compounds for selective inhibition of protein arginine methyltransferase 1. J Med Chem (2014) 0.82
Design of small molecule epigenetic modulators. Bioorg Med Chem Lett (2013) 0.81
Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1. PLoS One (2013) 0.80
Identification and validation of novel PERK inhibitors. J Chem Inf Model (2014) 0.79
Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening. PLoS One (2013) 0.77
Exploration of cyanine compounds as selective inhibitors of protein arginine methyltransferases: synthesis and biological evaluation. J Med Chem (2015) 0.77
Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis. Front Mol Biosci (2015) 0.77
Inhibitors of Protein Methyltransferases and Demethylases. Chem Rev (2017) 0.76
Discovery of Decamidine as a New and Potent PRMT1 Inhibitor. Medchemcomm (2017) 0.75
Arginine methylation an emerging regulator of protein function. Mol Cell (2005) 6.49
Histone arginine methylation regulates pluripotency in the early mouse embryo. Nature (2007) 4.55
Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol (2007) 2.14
Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate (2002) 2.05
Small molecule regulators of protein arginine methyltransferases. J Biol Chem (2004) 1.99
Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J Biol Chem (2001) 1.77
Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem (1998) 1.36
Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med Res Rev (2008) 1.32
The antifungal antibiotic sinefungin as a very active inhibitor of methyltransferases and of the transformation of chick embryo fibroblasts by Rous sarcoma virus. Biochem Biophys Res Commun (1978) 1.22
Asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Regul Integr Comp Physiol (2009) 1.20
Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem (2007) 1.16
epigenetic multiple ligands: mixed histone/protein methyltransferase, acetyltransferase, and class III deacetylase (sirtuin) inhibitors. J Med Chem (2008) 1.13
A glycine-arginine domain in control of the human MRE11 DNA repair protein. Mol Cell Biol (2008) 1.13
A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett (2007) 1.09
Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. Curr Med Chem (2004) 1.08
Bisubstrate Inhibitors of the MYST HATs Esa1 and Tip60. Bioorg Med Chem (2008) 1.05
Discovery and mechanistic study of a class of protein arginine methylation inhibitors. J Med Chem (2010) 1.02
The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation. Cell Res (2011) 0.99
Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II. J Vasc Res (2007) 0.97
Small molecule inhibitors of histone arginine methyltransferases: homology modeling, molecular docking, binding mode analysis, and biological evaluations. J Med Chem (2007) 0.95
Discovery of selective inhibitors against EBNA1 via high throughput in silico virtual screening. PLoS One (2010) 0.94
Acyl derivatives of p-aminosulfonamides and dapsone as new inhibitors of the arginine methyltransferase hPRMT1. Bioorg Med Chem (2011) 0.93
Virtual screening and biological characterization of novel histone arginine methyltransferase PRMT1 inhibitors. ChemMedChem (2009) 0.91
Identification of BRAF inhibitors through in silico screening. J Med Chem (2008) 0.88
Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors. J Mol Model (2011) 0.87
A dual-mode fluorescence strategy for screening HAT modulators. Bioconjug Chem (2009) 0.86
Chemical and biochemical approaches in the study of histone methylation and demethylation. Med Res Rev (2012) 0.85
Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase. Bioorg Med Chem Lett (2011) 0.81
Integrating molecular design resources within modern drug discovery research: the Roche experience. Drug Discov Today (2006) 0.81
Chromatin modifications as targets for new anticancer drugs. Arch Pharm (Weinheim) (2005) 0.81
Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity. J Chem Inf Model (2010) 0.80
3D-QSAR based pharmacophore modeling and virtual screening for identification of novel pteridine reductase inhibitors. J Mol Model (2011) 0.79
SPARX, a new environment for Cryo-EM image processing. J Struct Biol (2006) 4.66
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science (2009) 4.45
Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature (2010) 3.59
Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science (2013) 3.17
Predicting protein-protein interactions based only on sequences information. Proc Natl Acad Sci U S A (2007) 3.06
Molecular mimicry regulates ABA signaling by SnRK2 kinases and PP2C phosphatases. Science (2011) 2.52
Thymine DNA glycosylase specifically recognizes 5-carboxylcytosine-modified DNA. Nat Chem Biol (2012) 2.45
Altered functional connectivity and small-world in mesial temporal lobe epilepsy. PLoS One (2010) 2.37
PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics (2008) 2.35
TarFisDock: a web server for identifying drug targets with docking approach. Nucleic Acids Res (2006) 2.26
Estimation of variance in single-particle reconstruction using the bootstrap technique. J Struct Biol (2006) 2.10
Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate (2002) 2.05
The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol (2010) 1.98
An NMR approach to structural proteomics. Proc Natl Acad Sci U S A (2002) 1.95
Structural basis for molecular recognition at serotonin receptors. Science (2013) 1.86
Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology (2006) 1.75
Mechanically induced titin kinase activation studied by force-probe molecular dynamics simulations. Biophys J (2004) 1.70
Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer (2007) 1.68
Halogen bonding--a novel interaction for rational drug design? J Med Chem (2009) 1.68
Default mode network abnormalities in mesial temporal lobe epilepsy: a study combining fMRI and DTI. Hum Brain Mapp (2010) 1.62
Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol (2008) 1.57
Epigenetic regulation of phosphatidylinositol 3,4,5-triphosphate-dependent Rac exchanger 1 gene expression in prostate cancer cells. J Biol Chem (2011) 1.52
A nonproton ligand sensor in the acid-sensing ion channel. Neuron (2010) 1.52
Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr Relat Cancer (2006) 1.50
PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res (2010) 1.50
Structural basis for the regulation of cysteine-protease activity by a new class of protease inhibitors in Plasmodium. Structure (2011) 1.46
Evaluation of the tubulin-bound paclitaxel conformation: synthesis, biology, and SAR studies of C-4 to C-3' bridged paclitaxel analogues. J Med Chem (2007) 1.42
Inhibition of high glucose-induced erythrocyte phosphatidylserine exposure by leupeptin and disaccharides. Cryobiology (2007) 1.41
Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate (2006) 1.40
Crystal structure of HAb18G/CD147: implications for immunoglobulin superfamily homophilic adhesion. J Biol Chem (2008) 1.38
Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformation. J Am Chem Soc (2007) 1.34
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest (2013) 1.34
Reducing friction by chemically modifying the surface of extrasynovial tendon grafts. J Orthop Res (2004) 1.33
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist. Anal Biochem (2004) 1.29
MYST protein acetyltransferase activity requires active site lysine autoacetylation. EMBO J (2011) 1.29
Conformational transition of amyloid beta-peptide. Proc Natl Acad Sci U S A (2005) 1.28
Structure-based discovery of inhibitors of the YycG histidine kinase: new chemical leads to combat Staphylococcus epidermidis infections. BMC Microbiol (2006) 1.27
Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis (2002) 1.27
Structure of Vps75 and implications for histone chaperone function. Proc Natl Acad Sci U S A (2008) 1.27
[6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res (2009) 1.26
Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int J Cancer (2006) 1.26
Peptide deformylase is a potential target for anti-Helicobacter pylori drugs: reverse docking, enzymatic assay, and X-ray crystallography validation. Protein Sci (2006) 1.25
Virtual screening on natural products for discovering active compounds and target information. Curr Med Chem (2003) 1.25
Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog (2011) 1.25
Gene flow from genetically modified rice to its wild relatives: Assessing potential ecological consequences. Biotechnol Adv (2009) 1.24
Gliding characteristics and gap formation for locking and grasping tendon repairs: a biomechanical study in a human cadaver model. J Hand Surg Am (2004) 1.23
Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. ACS Med Chem Lett (2012) 1.22
Oxidative stress and the regulation of complement activation in human glaucoma. Invest Ophthalmol Vis Sci (2010) 1.21
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett (2007) 1.20
Protein cysteine phosphorylation of SarA/MgrA family transcriptional regulators mediates bacterial virulence and antibiotic resistance. Proc Natl Acad Sci U S A (2012) 1.18
Accelerated aging in glaucoma: immunohistochemical assessment of advanced glycation end products in the human retina and optic nerve head. Invest Ophthalmol Vis Sci (2007) 1.17
Inherent dynamics of the acid-sensing ion channel 1 correlates with the gating mechanism. PLoS Biol (2009) 1.17
Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate (2007) 1.17
Neurodegenerative and inflammatory pathway components linked to TNF-α/TNFR1 signaling in the glaucomatous human retina. Invest Ophthalmol Vis Sci (2011) 1.17
Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol (2011) 1.16
Structural basis for dimerization in DNA recognition by Gal4. Structure (2008) 1.16
Mechanisms of immune system activation in glaucoma: oxidative stress-stimulated antigen presentation by the retina and optic nerve head glia. Invest Ophthalmol Vis Sci (2007) 1.16
Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology (2012) 1.16
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther (2007) 1.15
Interface-confined ferrous centers for catalytic oxidation. Science (2010) 1.15
Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J Virol (2005) 1.15
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer (2003) 1.15
Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine (2008) 1.15
Human TH9 cells are skin-tropic and have autocrine and paracrine proinflammatory capacity. Sci Transl Med (2014) 1.15
Arginine Methylation Initiates BMP-Induced Smad Signaling. Mol Cell (2013) 1.14
Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol (2003) 1.13
Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene (2005) 1.13
Administration of a CO-releasing molecule induces late preconditioning against myocardial infarction. J Mol Cell Cardiol (2004) 1.12
Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer. BMC Syst Biol (2013) 1.12
Quorum-sensing agr mediates bacterial oxidation response via an intramolecular disulfide redox switch in the response regulator AgrA. Proc Natl Acad Sci U S A (2012) 1.11
Structural basis for catalytic and inhibitory mechanisms of beta-hydroxyacyl-acyl carrier protein dehydratase (FabZ). J Biol Chem (2007) 1.11
Arctigenin effectively ameliorates memory impairment in Alzheimer's disease model mice targeting both β-amyloid production and clearance. J Neurosci (2013) 1.10
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr Relat Cancer (2005) 1.10
pH-dependent conformational flexibility of the SARS-CoV main proteinase (M(pro)) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J Mol Biol (2005) 1.09
Structural and functional characterization of Falcipain-2, a hemoglobinase from the malarial parasite Plasmodium falciparum. J Biol Chem (2006) 1.09
Complete genome sequence of Bacillus amyloliquefaciens LL3, which exhibits glutamic acid-independent production of poly-γ-glutamic acid. J Bacteriol (2011) 1.07
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2010) 1.07
Conformational dynamics of the nicotinic acetylcholine receptor channel: a 35-ns molecular dynamics simulation study. J Am Chem Soc (2005) 1.07
Phosphorylation-dependent interaction with 14-3-3 in the regulation of bad trafficking in retinal ganglion cells. Invest Ophthalmol Vis Sci (2008) 1.07
AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. J Cell Mol Med (2012) 1.06
Assessment of non-invasive intervertebral motion measurements in the lumbar spine. J Biomech (2005) 1.06
Ligand-binding regulation of LXR/RXR and LXR/PPAR heterodimerizations: SPR technology-based kinetic analysis correlated with molecular dynamics simulation. Protein Sci (2005) 1.06
Induced-fit or preexisting equilibrium dynamics? Lessons from protein crystallography and MD simulations on acetylcholinesterase and implications for structure-based drug design. Protein Sci (2008) 1.05
Chromium is not an essential trace element for mammals: effects of a "low-chromium" diet. J Biol Inorg Chem (2010) 1.05
EEG-fMRI study on the interictal and ictal generalized spike-wave discharges in patients with childhood absence epilepsy. Epilepsy Res (2009) 1.05
Bisubstrate Inhibitors of the MYST HATs Esa1 and Tip60. Bioorg Med Chem (2008) 1.05
Mechanics of channel gating of the nicotinic acetylcholine receptor. PLoS Comput Biol (2008) 1.05
Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med (2012) 1.04
Computational drug discovery. Acta Pharmacol Sin (2012) 1.04
Malonyl-CoA: acyl carrier protein transacylase from Helicobacter pylori: Crystal structure and its interaction with acyl carrier protein. Protein Sci (2007) 1.04
Hemoglobin expression and regulation in glaucoma: insights into retinal ganglion cell oxygenation. Invest Ophthalmol Vis Sci (2009) 1.03
Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A. Biochem Biophys Res Commun (2004) 1.03